Phase 3 SOLAR Trials Begin with Prostate Cancer Patient Enrollment

Curium, a prominent figure in the realm of nuclear medicine, has made a significant stride with the commencement of its SOLAR clinical trials. The first trial, known as SOLAR-STAGE, is a Phase 3 study that is set to assess the efficacy of copper Cu 64 PSMA I&T PET/CT in the staging process for men newly diagnosed with prostate cancer. This study is specifically targeting those with unfavorable intermediate-risk, high-risk, or very-high-risk profiles who are opting for radical prostatectomy along with pelvic lymph node dissection.

In tandem, the SOLAR-RECUR trial, also a Phase 3 endeavor, is geared towards examining the diagnostic capabilities of the same PET/CT imaging technique in men suspected of having a biochemical recurrence of prostate cancer post radical prostatectomy or radiation therapy.

The trials are actively recruiting participants at various locations throughout the United States, with plans to extend to European sites later in the year. Dr. Sakir Mutevelic, Curium’s Chief Medical Officer, highlighted the importance of these trials, emphasizing Curium's dedication to advancing cancer diagnostics through its expertise in nuclear medicine.

Amy Bartalotta, Vice President of Clinical Operations, detailed the company's strategy to involve a wide demographic of patients, including those from minority groups that are disproportionately impacted by prostate cancer and are less likely to undergo screening. To this end, Curium has enlisted 50 U.S. sites and over 30 European sites for the trials. The first participants to be enrolled and scanned were at XCancer®, under the guidance of Dr. Luke Nordquist.

Curium, with its manufacturing facilities spread across Europe and the United States, serves over 14 million patients annually with its range of SPECT, PET, and therapeutic radiopharmaceutical solutions for critical illnesses. The company's name is a tribute to the pioneering work of Marie and Pierre Curie, whose legacy in radioactive materials research is honored in the company's commitment to nuclear medicine.